Mirabegron and Cefazolin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mirabegron (mirabegron) and Cefazolin (cefazolin sodium). Common drug interactions include dyskinesia among females and colon dysplasia among males.

The phase IV clinical study analyzes what interactions people have when they take Mirabegron and Cefazolin. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Mirabegron?

Mirabegron has active ingredients of mirabegron. It is often used in urge incontinence. eHealthMe is studying from 5,414 Mirabegron users. Check the latest studies of Mirabegron.

What is Cefazolin?

Cefazolin has active ingredients of cefazolin sodium. It is often used in infection. eHealthMe is studying from 15,157 Cefazolin users. Check the latest studies of Cefazolin.



On Jul, 31, 2026

20 people who take Mirabegron and Cefazolin together, and have interactions are studied.

Mirabegron and Cefazolin drug interactions.

What are the common drug interactions of Mirabegron and Cefazolin, by gender? *:

female:

  1. Dyskinesia (abnormality or impairment of voluntary movement)
  2. Constipation
  3. Chronic gastritis (long lasting infection of stomach lining)
  4. On and off phenomenon
  5. Spinal compression fracture (fracture due to spinal compression on bone)
  6. White blood cell count decreased
  7. Speech disorder
  8. Aspartate aminotransferase increased
  9. Pain
  10. Urinary tract infection

male:

  1. Colon dysplasia (abnormal growth or development of cells of colon)
  2. Renal failure acute (rapid kidney dysfunction)
  3. Cerebral infarction (less blood supply to brain resulting tissue damage)
  4. Confusional state
  5. Dehydration (dryness resulting from the removal of water)
  6. Febrile neutropenia (fever with reduced white blood cells)
  7. Lung abscess (pus in lungs)
  8. Lymphocyte count decreased
  9. Muscular weakness (muscle weakness)
  10. Neutropenia (an abnormally low number of neutrophils)

What are the common drug interactions of Mirabegron and Cefazolin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Abdominal discomfort
  2. Hypertension (high blood pressure)
  3. Radius fracture
  4. Chronic kidney disease
  5. Nephrogenic anaemia (anaemia due to kidney disease)
  6. Renal failure (kidney dysfunction)
  7. Renal tubular necrosis (death of kidney tubules)

60+:

  1. Dyskinesia (abnormality or impairment of voluntary movement)
  2. Constipation
  3. Urinary retention (the inability to completely or partially empty the bladder)
  4. Angina pectoris (chest pain due to ischemia of the heart muscle)
  5. Benign prostatic hyperplasia (benign enlargement of the prostate)
  6. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  7. Pyelonephritis acute (sudden inflammation of kidney caused by bacteria)
  8. Abdominal pain
  9. Anaemia (lack of blood)
  10. Anxiety

What are the existing conditions these people have? *

  1. Enlarged Prostate: 8 people, 40.00%
  2. Parkinson's Disease: 8 people, 40.00%
  3. Constipation: 7 people, 35.00%
  4. Back Pain: 6 people, 30.00%
  5. Insomnia (sleeplessness): 6 people, 30.00%
  6. Pain: 6 people, 30.00%
  7. Multiple Myeloma (cancer of the plasma cells): 6 people, 30.00%
  8. Oedema Peripheral (superficial swelling): 5 people, 25.00%
  9. The Flu (the flu is caused by an influenza virus): 4 people, 20.00%
  10. Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 4 people, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Mirabegron and Cefazolin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Mirabegron and Cefazolin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mirabegron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Cefazolin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Mirabegron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cefazolin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on mirabegron and cefazolin sodium (the active ingredients of Mirabegron and Cefazolin, respectively), and Mirabegron and Cefazolin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: